Extremely Normal

A Very 2020 Look at Food, Climate Change and Extreme Weather

Explore Your Topic

Quarterly Statement Q3 2020

Challenging third quarter вЂ“ Group outlook confirmed

Working together for Health for all, Hunger for none

Interview with Robert S. Greene

Prostate cancer: вЂњThe treatment conversation needs to start with quality of lifeвЂќ

Our Products

Can We Live Better?

Can 10 billion of us live better?

Finding Heart: Women and Cardiovascular Risk

Family Planning

100 Million Women by 2030 вЂ“ Choice for Every One of Them

Uses and Safety Record

LetвЂ™s Talk About Glyphosate

Links

Information for Patients

Modern Slavery Act Statement.pdf (PDF 2.05 MB)

Latest News

Share Price / Index

November 10, 2020 17:35 CEST

November 10, 2020 17:45 CEST

November 09, 2020

Not intended for U.S. and UK Media

Bayer submits marketing authorization applications for finerenone in the U.S. and the EU for patients with chronic kidney disease and type 2 diabetes

November 03, 2020

Bayer:

Challenging third quarter – Group outlook confirmed

October 26, 2020

Bayer acquires Asklepios BioPharmaceutical to broaden innovation base in cell and gene therapy

Advance Your Career

Why Bayer

Working at Bayer

Meet Our Employees

Open Jobs

PostDoc Modelling for Solubility Predictions (m/f/d)

Germany Wuppertal-Aprath

Chemikant (m/w/d) Tagschicht Lager und Versand

Germany HГјrth-Knapsack

Senior Engineering Manager Process Control Techology (m/f/d)

Explore Our Businesses

We address some of the world's most pressing global challenges and continue to develop new solutions. The population is constantly growing and its age is increasing. That is why it needs better medicines and high-quality food in sufficient quantities. Learn more about it here.

Pharmaceuticals

Consumer Health